Is ALNY or ANAB more undervalued in 2026?

CirclFi compares Alnylam Pharmaceuticals, Inc. (ALNY) and AnaptysBio, Inc. (ANAB) using 13 institutional-grade valuation models. ALNY has a Quality of Company score of 9.7/10 while ANAB scores 6.8/10.

Which is a better buy — ALNY or ANAB?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ALNY and ANAB valuations compare?

ALNY at $305.06 and ANAB at $57.02 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ALNY vs ANAB Valuation Comparison 2026 — Intrinsic Value Analysis

ALNY

Biotechnology

Alnylam Pharmaceuticals, Inc.

Quality

9.7

out of 10

Value Trap

SAFE

Price

$305.06

Last close

Models

11/13

Active

ANAB

Biotechnology

AnaptysBio, Inc.

Quality

6.8

out of 10

Value Trap

SAFE

Price

$57.02

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	ALNY Fair Value	ALNY Upside	ANAB Fair Value	ANAB Upside
Bayesian DCF	Intrinsic	$29.56	-90.3%	$19.98	-65.0%
Earnings Power Value	Intrinsic	$33.29	-89.1%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$221.49	-27.4%	$11.33	-80.1%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ALNY vs ANAB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ALNY vs ANAB — Which Stock Is More Undervalued?

ALNY scores higher with a 9.7/10 quality rating vs ANAB's 6.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Alnylam Pharmaceuticals, Inc. (ALNY) and AnaptysBio, Inc. (ANAB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ALNY currently trades at $305.06 with a QOC of 9.7/10, while ANAB trades at $57.02 with a QOC of 6.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).